AlphAIAlphAI — Financial news for AI agents
SEC EDGAR 8-K$DCTH

Delcath Systems Reports Second Quarter 2026 Results and Business Highlights

DELCATH SYSTEMS, INC. (DCTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Delcath Systems Reports Second Quarter 2026 Results and Business Highlights Increases 2026 Revenue Guidance to a Range of $104M to $108M Conference Call Today at 8:30 a.m. Eastern Time QUEENSBURY, NY – August 6, 2026, Delcath Systems, Inc. (Nasdaq: DCTH), an interven

Original reporting
SEC EDGAR 8-K
Published Aug 6, 2026, 12:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 1:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$DCTH
Bullish
high confidence
Mentioned
$DCTH
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$DCTHBullishMed
01

Why it matters

Traders can reprice DCTH based on the raised 2026 revenue range ($104M-$108M) and the stated driver of at least 28% HEPZATO KIT volume growth over 2025, alongside Q2 operating cash flow and cash balance.

02

Market read

A company-specific earnings and guidance update with explicit full-year revenue and margin ranges, plus operational metrics (treatment centers, HEPZATO volume growth).

03

What to watch

R&D and SG&A both rose in Q2, and the filing does not provide updated trial endpoints beyond dosing and retrospective presentations, which may limit upside if investors demand prospective efficacy data.

Relevance 7/10Novelty 8/10Timing: filed pre-market today, guidance and Q2 results digest immediately

Background

SEC 8-K Item 2.02 with Exhibit 99.1 covering Delcath’s Q2 2026 results, business highlights, and full-year 2026 financial guidance.

Company-level read

Ticker impact

$DCTHBullishHigh confidence
Context

Delcath reported Q2 revenue of $29.1M, raised 2026 guidance to $104M-$108M, and reiterated positive adjusted EBITDA outlook.

Expected impact

Likely positive bias for the next session and into guidance digestion, with focus on whether HEPZATO volume growth sustains.

Evidence & confidence

The filing discloses fresh, decision-relevant numbers: Q2 revenue and margins, cash balance, and a full-year revenue range tied to at least 28% HEPZATO KIT volume growth over 2025.

Market effects

Sector

Reinforces investor appetite for interventional oncology and liver-directed delivery platforms, potentially supporting peer sentiment.

Regional

Primarily US small-cap biotech sentiment; limited direct regional spillover beyond healthcare.

Global

Europe device revenue contribution is mentioned, but the disclosed catalyst is company-specific rather than global policy or trial readout.

Counterpoint

What could challenge this read

Adjusted EBITDA declined year over year (to $7.6M from $9.8M), so the market may question whether guidance relies on volume growth that is not yet translating into profitability.

Key entities

  • company
    Delcath Systems, Inc.

    Interventional oncology company reporting Q2 2026 results and raising full-year 2026 revenue guidance.

  • product
    HEPZATO KIT

    Primary revenue driver in the US, with reported Q2 revenue of $27.1M and guidance tied to volume growth.

  • product
    CHEMOSAT

    Europe revenue contributor, with reported Q2 revenue of $2.0M.

Read at source← All news

Related articles

$DCTHHighAI 8/10

Delcath Systems Inc (DCTH) (Q3 2026) Earnings Call Highlights: Record Revenue, Raised

Delcath Systems (DCTH) reported Q3 2026 revenue of $35.1M, up 71% YoY, driven by HEPZATO KIT sales. CEO Gerard Michel cited therapy adoption, physician demand, and expanded capacity as growth drivers. The company raised full-year revenue guidance to $115M-$117M. Q4 guidance implies a step-down due to holiday impact, with new patient starts expected to slow. The Phase II colorectal cancer trial interim analysis is now expected in Q2 or Q3 2027.

finance.yahoo.com
$EDSAMedAI 8/10

Healthcare Stocks Rally: EDSA And DCTH Jump 30%, VIR And IMVT Also Gain

Edesa Biotech (EDSA) and Delcath Systems (DCTH) shares rose 30% after signing a licensing deal and reporting strong Q3 results, respectively. Immunovant (IMVT) and Vir Biotechnology (VIR) shares gained 13% and 14% following positive clinical trial data. EDSA received $12M upfront, DCTH raised FY26 revenue outlook, IMVT met primary endpoint, and VIR showed undetectable HDV RNA in 28 patients.

rttnews.com
$DCTHMed

Delcath (DCTH) Q3 2026 Earnings Call Transcript

Delcath (DCTH) reported Q3 2026 revenue of $35.1M, up 71% YoY, driven by HEPZATO KIT adoption. The company added new treatment centers, including AdventHealth, and expects 36 centers by year-end. Clinical trials are progressing, with a Phase II colorectal trial on track for interim analysis in mid-2027. Full-year revenue guidance was raised to $115M-$117M, with Q4 expected to grow 25%-34% YoY.

finance.yahoo.com
$DCTHMed

Delcath Systems Reports 70% Revenue Growth in Q3 2026 and Raises Full-Year Guidance to $115 Million–$117 Million

Delcath Systems (DCTH) reported Q3 2026 revenue of $35.1M, up 70% YoY, driven by higher sales of its liver cancer treatment products. The company raised its full-year revenue guidance to $115M–$117M. Net income increased to $7.0M, and gross margin improved to 89%. HEPZATO KIT revenue grew 69% to $32.7M, while European CHEMOSAT revenue rose to $2.4M. Adjusted EBITDA increased to $11.5M, and operating cash flow reached $8.2M. Delcath also advanced its clinical development programs.

finance.yahoo.com
$DCTHMed

Delcath Systems Q3 Earnings Call Highlights

Delcath Systems (DCTH) raised its 2026 revenue guidance to $115M-$117M, projecting HEPZATO KIT volume growth of at least 41% over 2025. Q4 revenue is expected to be $25.8M-$27.8M, down sequentially but up 25%-34% year-over-year, due to holiday scheduling. Growth is attributed to increased use of HEPZATO, patient awareness, and expanded capacity at centers like MD Anderson and Mass General.

finance.yahoo.com